Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

IRA S SMALBERG

Allopathic & Osteopathic Physicians Radiology Diagnostic Radiology

NPI
1952356255
CMS profile
959975
Location
SANTA MONICA, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$108,196.10

105 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $108,154.66 103
Food and Beverage $41.44 2

By paying entity

PY2019 · entire year · sorted by reported total

Paying entityAmountRecords
Merck Sharp & Dohme Corporation $104,954.66 101
Seattle Genetics, Inc. $3,200.00 2
Siemens Medical Solutions USA, Inc. $41.44 2

Page 3 of 3; records 101–105 of 105 matching records. This page contains 5 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

IRA S SMALBERG

NPI 1952356255 · CMS profile ID 959975

Allopathic & Osteopathic Physicians / Radiology / Diagnostic Radiology

SANTA MONICA, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 3; records 101–105 of 105 matching records. This page contains 5 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1952356255?year=2019&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
IRA S SMALBERG, NPI 1952356255, CMS profile ID 959975. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–105 of 105 matching records. This page contains 5 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1952356255?year=2019&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). IRA S SMALBERG, NPI 1952356255, CMS profile ID 959975. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–105 of 105 matching records. This page contains 5 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1952356255?year=2019&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
IRA S SMALBERG, NPI 1952356255, CMS profile ID 959975, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–105 of 105 matching records. This page contains 5 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1952356255?year=2019&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

105 matching records · $108,196.10 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 105 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–105 of 105.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Merck Sharp & Dohme Corporation $185.0001/03/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695770171 CMS
Merck Sharp & Dohme Corporation $180.0001/03/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695770457 CMS
Merck Sharp & Dohme Corporation $2,075.0001/03/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695770459 CMS
Merck Sharp & Dohme Corporation $255.0001/03/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695770465 CMS
Merck Sharp & Dohme Corporation $285.0001/03/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695770469 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $108,196.10 105
PY2020 $83,646.58 130
PY2021 $54,692.50 81
PY2022 $101,457.50 15
PY2023 $102,915.00 28
PY2024 $450.00 2

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
Generated from
OP_DTL_GNRL_PGYR2024_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $73,465.00 25
PY2024 Principal investigator $47,733.11 15
PY2023 Recipient $292,467.50 14
PY2023 Principal investigator $14,727.10 10
PY2022 Recipient $209,708.35 30
PY2022 Principal investigator $630.00 1
PY2021 Recipient $250,315.00 15
PY2021 Principal investigator $39,205.00 18
PY2020 Recipient $365,788.25 13
PY2020 Principal investigator $179,610.00 34
PY2019 Recipient $421,410.58 15
PY2019 Principal investigator $148,362.95 19

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

25 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Boehringer Ingelheim International GmbH $4,055.00 12/19/2025 Non-covered Recipient Entity
Radmetrix Inc
Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours No dispute reported 06/30/2026 1220739611
Principal investigator 1 Boehringer Ingelheim International GmbH $1,100.00 11/06/2025 Non-covered Recipient Entity
Radmetrix Inc
Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours No dispute reported 06/30/2026 1220739609
Principal investigator 1 BeOne Medicines Ltd. $180.00 09/16/2025 Non-covered Recipient Entity
RADMETRIX
A Single-Arm, Open-Label, Multicenter Phase 1/2 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of BCL2 Inhibitor BGB-11417 in Patients With Relapsed or Refractory Mantle Cell Lymphoma No dispute reported 06/30/2026 1190344783
Principal investigator 1 Boehringer Ingelheim International GmbH $660.00 09/02/2025 Non-covered Recipient Entity
Radmetrix Inc
Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours No dispute reported 06/30/2026 1220739607
Principal investigator 1 BeOne Medicines Ltd. $180.00 08/12/2025 Non-covered Recipient Entity
RADMETRIX
A Single-Arm, Open-Label, Multicenter Phase 1/2 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of BCL2 Inhibitor BGB-11417 in Patients With Relapsed or Refractory Mantle Cell Lymphoma No dispute reported 06/30/2026 1190344779
Principal investigator 1 BeOne Medicines Ltd. $450.00 07/15/2025 Non-covered Recipient Entity
RADMETRIX
A Single-Arm, Open-Label, Multicenter Phase 1/2 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of BCL2 Inhibitor BGB-11417 in Patients With Relapsed or Refractory Mantle Cell Lymphoma No dispute reported 06/30/2026 1190344775
Principal investigator 1 Boehringer Ingelheim International GmbH $1,250.00 06/24/2025 Non-covered Recipient Entity
Radmetrix Inc
Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours No dispute reported 06/30/2026 1220739605
Principal investigator 1 BeiGene, Ltd. $630.00 05/20/2025 Non-covered Recipient Entity
RADMETRIX
An Open-Label, Multicenter Phase 2 Study to Evaluate the Efficacy and Safety of the BCL2 Inhibitor Sonrotoclax (BGB-11417) as Monotherapy and in Combination With Zanubrutinib (BGB-3111) in Patients With Waldenström Macroglobulinemia No dispute reported 06/30/2026 1190321438
Principal investigator 1 BeiGene, Ltd. $360.00 05/20/2025 Non-covered Recipient Entity
RADMETRIX
An Open-Label, Multicenter Phase 2 Study to Evaluate the Efficacy and Safety of the BCL2 Inhibitor Sonrotoclax (BGB-11417) as Monotherapy and in Combination With Zanubrutinib (BGB-3111) in Patients With Waldenström Macroglobulinemia No dispute reported 06/30/2026 1190321440
Principal investigator 1 AstraZeneca UK Limited $6,570.00 05/13/2025 Non-covered Recipient Entity
IRA SMALBERG MD INC
a randomized,phase third study of rilvegostomig in combination with fluoropyrimidine and trastuzumab deruxtecan versus trastuzumab,chemotherapy,and pembrolizumab for the first line treatment of positive gastric cancer No dispute reported 06/30/2026 1185552081
Principal investigator 1 BeiGene, Ltd. $3,510.00 05/13/2025 Non-covered Recipient Entity
RADMETRIX
A Single-Arm, Open-Label, Multicenter Phase 1/2 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of BCL2 Inhibitor BGB-11417 in Patients With Relapsed or Refractory Mantle Cell Lymphoma No dispute reported 06/30/2026 1190321070
Principal investigator 1 BeiGene, Ltd. $1,870.00 05/13/2025 Non-covered Recipient Entity
RADMETRIX
An Open-Label, Multicenter Phase 2 Study to Evaluate the Efficacy and Safety of the BCL2 Inhibitor Sonrotoclax (BGB-11417) as Monotherapy and in Combination With Zanubrutinib (BGB-3111) in Patients With Waldenström Macroglobulinemia No dispute reported 06/30/2026 1190321434
Principal investigator 1 BeiGene, Ltd. $1,600.00 05/13/2025 Non-covered Recipient Entity
RADMETRIX
An Open-Label, Multicenter Phase 2 Study to Evaluate the Efficacy and Safety of the BCL2 Inhibitor Sonrotoclax (BGB-11417) as Monotherapy and in Combination With Zanubrutinib (BGB-3111) in Patients With Waldenström Macroglobulinemia No dispute reported 06/30/2026 1190321436
Principal investigator 1 BeiGene, Ltd. $2,280.00 05/06/2025 Non-covered Recipient Entity
RADMETRIX
A Single-Arm, Open-Label, Multicenter Phase 1/2 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of BCL2 Inhibitor BGB-11417 in Patients With Relapsed or Refractory Mantle Cell Lymphoma No dispute reported 06/30/2026 1190321072
Principal investigator 1 BeiGene, Ltd. $180.00 05/06/2025 Non-covered Recipient Entity
RADMETRIX
An Open-Label, Multicenter Phase 2 Study to Evaluate the Efficacy and Safety of the BCL2 Inhibitor Sonrotoclax (BGB-11417) as Monotherapy and in Combination With Zanubrutinib (BGB-3111) in Patients With Waldenström Macroglobulinemia No dispute reported 06/30/2026 1190321428
Principal investigator 1 BeiGene, Ltd. $90.00 05/06/2025 Non-covered Recipient Entity
RADMETRIX
An Open-Label, Multicenter Phase 2 Study to Evaluate the Efficacy and Safety of the BCL2 Inhibitor Sonrotoclax (BGB-11417) as Monotherapy and in Combination With Zanubrutinib (BGB-3111) in Patients With Waldenström Macroglobulinemia No dispute reported 06/30/2026 1190321432
Principal investigator 1 BeiGene, Ltd. $180.00 04/08/2025 Non-covered Recipient Entity
RADMETRIX
An Open-Label, Multicenter Phase 2 Study to Evaluate the Efficacy and Safety of the BCL2 Inhibitor Sonrotoclax (BGB-11417) as Monotherapy and in Combination With Zanubrutinib (BGB-3111) in Patients With Waldenström Macroglobulinemia No dispute reported 06/30/2026 1190321430
Principal investigator 1 BeiGene, Ltd. $1,710.00 02/25/2025 Non-covered Recipient Entity
RADMETRIX
A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of Bcl-2 Inhibitor BGB-11417 in Adult Patients With Mature B-cell Malignancies No dispute reported 06/30/2026 1190323230
Principal investigator 1 BeiGene, Ltd. $540.00 02/25/2025 Non-covered Recipient Entity
RADMETRIX
A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of Bcl-2 Inhibitor BGB-11417 in Adult Patients With Mature B-cell Malignancies No dispute reported 06/30/2026 1190323234
Principal investigator 1 BeiGene, Ltd. $270.00 02/18/2025 Non-covered Recipient Entity
RADMETRIX
A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of Bcl-2 Inhibitor BGB-11417 in Adult Patients With Mature B-cell Malignancies No dispute reported 06/30/2026 1190323214
Principal investigator 1 AstraZeneca UK Limited $19,740.00 01/28/2025 Non-covered Recipient Entity
IRA SMALBERG MD INC
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of Durvalumab Monotherapy or in Combination With Bevacizumab as Adjuvant Therapy in Patients with Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation No dispute reported 06/30/2026 1185552079
Principal investigator 1 BeiGene, Ltd. $90.00 01/28/2025 Non-covered Recipient Entity
RADMETRIX
A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of Bcl-2 Inhibitor BGB-11417 in Adult Patients With Mature B-cell Malignancies No dispute reported 06/30/2026 1190323212
Principal investigator 1 BeiGene, Ltd. $270.00 01/28/2025 Non-covered Recipient Entity
RADMETRIX
A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of Bcl-2 Inhibitor BGB-11417 in Adult Patients With Mature B-cell Malignancies No dispute reported 06/30/2026 1190323216
Principal investigator 1 BeiGene, Ltd. $2,520.00 01/28/2025 Non-covered Recipient Entity
RADMETRIX
A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of Bcl-2 Inhibitor BGB-11417 in Adult Patients With Mature B-cell Malignancies No dispute reported 06/30/2026 1190323232
Principal investigator 1 Amgen Inc. $23,180.00 01/09/2025 Non-covered Recipient Entity
RADMETRIX INC
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Tarlatamab Therapy in Subjects With Limited-Stage Small-Cell Lung Cancer (LS-SCLC) Who Have Not Progressed Following Concurrent Chemoradiation Therapy No dispute reported 06/30/2026 1246647040